Targeting SWI/SNF complex function in cancer

Projektinformationen

TARGETSS

ID Finanzhilfevereinbarung: 796973

DOI 10.3030/796973

Das Projekt endete am 6 Juni 2020

EK-Unterschriftsdatum 28 August 2018

Startdatum 1 September 2019

Enddatum 31 August 2021

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten € 175 866,00

EU-Beitrag € 175 866,00

Koordiniert durch

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Ireland

Ziel

Cancer can be considered a disease of gene control; since dysregulated patterns of gene expression are a feature of all tumours. Excitingly, targeting the underlying epigenetic mechanisms that promote oncogenic gene expression in cancer cells is providing significant opportunities for cancer drug development. Indeed, initial successes in this area may soon be leveraged for the benefit of cancer patients. Expanding European research capabilities in this area is essential, since approximately 1.5 million people die from cancer each year in Europe; and projections indicate that this number will increase in the coming decades. The work described in this application is at the cutting-edge of cancer drug target discovery, and drug development. My work identified the SWI/SNF complex component BRD9 as a novel drug target in several malignancies; and drug development efforts have led to first-in-class BRD9 degrader compounds. Testing the in vivo efficacy of these novel compounds as anti-cancer agents (WP1) will be essential if we are to translate these compounds to clinical investigations. Moreover, the work described in WP2/3 will be essential to fully exploit the potential of BRD9 as a drug target and identify additional opportunities for future drug development. My expertise in the areas of epigenetics and drug development make me the ideal candidate to pursue the outlined research program. Moreover, the support of this Action will give me the opportunity to develop further as an independent researcher; both in terms of technical expertise and transferable skills. These additional skills will allow me to achieve my long-term career goal of establishing my own independent research program, focusing on cancer epigenetics/drug development within a European context. Dissemination of the research findings associated with this Action will increase Europe's profile in cancer epigenetics research, and hopefully lead to increased public engagement in this important area of study.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › genetics › epigenetics

Schlüsselbegriffe

• Cancer
• SWI
• SNF complex
• CRISPR
• Cas9
• PROTAC
• degrader
• targeted therapy
• sarcoma
• leukemia
• rhabdoid tumour

Programm/Programme

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Thema/Themen

• MSCA-IF-2017 - Individual Fellowships

Aufforderung zur Vorschlagseinreichung

H2020-MSCA-IF-2017

Finanzierungsplan

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Koordinator

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

• Netto-EU-Beitrag: € 175 866,00
• Adresse: COLLEGE GREEN TRINITY COLLEGE ; D02 CX56 DUBLIN 2 ; Irland
• Region: Ireland › Eastern and Midland › Dublin
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: € 175 866,00